Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSR | P00390 | 2/20 | 0.55 |
| ▸ | GRM8 | O00222 | 2/20 | 0.55 |
| ▸ | GRM6 | O15303 | 2/20 | 0.55 |
| ▸ | GRM7 | Q14831 | 2/20 | 0.55 |
| ▸ | GRM4 | Q14833 | 2/20 | 0.55 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.55 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.55 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.55 |
| ▸ | GRM5 | P41594 | 1/20 | 0.55 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.55 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.55 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.55 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.55 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.55 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.55 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.55 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.55 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.55 |
| ▸ | GRIK2 | Q13002 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2263983 | 1.00 | GSR (0.55) | GSRGRM8GRM6GRM7GRM4 | |
| SCHEMBL2263990 | 1.00 | GSR (0.55) | GSRGRM8GRM6GRM7GRM4 | |
| SCHEMBL29741400 | 0.94 | GSR (0.57) | GSRGRM8GRM6GRM7GRM4 | |
| SCHEMBL29485083 | 0.90 | GSR (0.61) | GSRGRM8GRM6GRM7GRM4 | |
| SCHEMBL28717409 | 0.87 | ARG2 (0.50) | GSRGRM8GRM6GRM7GRM4 | |
| SCHEMBL2548650 | 0.87 | GSR (0.53) | GSRGRM8GRM6GRM7GRM4 | |
| SCHEMBL43621 | 0.87 | GSR (0.53) | GSRGRM8GRM6GRM7GRM4 | |
| Water SCHEMBL380639 | 0.85 | GSR (0.52) | GSRGRM8GRM6GRM7GRM4 | |
| SCHEMBL448753 | 0.83 | GSR (0.77) | GSRCYP1A2ARG2ARG1ALOX15 | |
| SCHEMBL31612943 | 0.83 | GSR (0.53) | GSRGRM8GRM6GRM7GRM4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 115 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119317362-A | Pet food compositions and methods for reducing metabolites associated with protein spoilage in felines | 希尔氏宠物营养品公司 | 2025-01-14 | — | — | CN | claimed |
| EP-4391825-A1 | PET FOOD COMPOSITIONS AND METHOD FOR REDUCING METABOLITES ASSOCIATED WITH PROTEIN PUTREFACTION IN A FELINE | Hill's Pet Nutrition, Inc. (US) | 2024-07-03 | — | — | EP | claimed |
| US-20230404951-A1 | Pet Food Compositions | HILL'S PET NUTRITION, INC. (US) | 2023-12-21 | — | — | US | claimed |
| WO-2023244712-A1 | PET FOOD COMPOSITIONS AND METHOD FOR REDUCING METABOLITES ASSOCIATED WITH PROTEIN PUTREFACTION IN A FELINE | HILL'S PET NUTRITION, INC. (US) | 2023-12-21 | — | — | WO | claimed |
| US-20180340926-A1 | METHODS FOR IMPROVING DIABETES MANAGEMENT | JOURNEY BIOSCIENCES, LLC | 2018-11-29 | — | — | US | claimed |
| EP-3341720-A1 | METHODS FOR IMPROVING DIABETES MANAGEMENT | PreventAGE Healthcare, LLC (US) | 2018-07-04 | — | — | EP | claimed |
| WO-2017039743-A1 | METHODS FOR IMPROVING DIABETES MANAGEMENT | PREVENTAGE HEALTH CARE LLC (US) | 2017-03-09 | — | — | WO | claimed |
| US-20140154257-A1 | Materials and methods for diagnosing and treating asthma and dietary Fru-AGEs related disorders including auto-immune and other diseases found to be associated with elevated RAGE. The specification describes methods to identify and make dietary derived advanced glycation end-products, known as Fru-AGEs, Fru-AGE-haptens, and Fru-AGE immune complexes, and to make monoclonal and polyclonal antibodies to this plurality of bio-molecules for use in immunoassays and for use as therapeutic agents | DECHRISTOPHER LUANNE ROBALO (US) | 2014-06-05 | — | — | US | claimed |
| US-20050124071-A1 | Methods and compositions for diagnosing musculoskeletal, arthritic and joint disorders by biomarker dating | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2005-06-09 | — | — | US | claimed |
| WO-2005033705-A1 | METHODS AND COMPOSITIONS FOR DIAGNOSING MUSCULOSKELETAL, ARTHRITIC AND JOINT DISORDERS BY BIOMARKER DATING | DUKE UNIVERSITY (US) | 2005-04-14 | — | — | WO | claimed |
| US-20260022384-A1 | ASPARAGINE SYNTHETASE INHIBITORS AND USES THEREOF | OSPEDALE SAN RAFFAELE S.R.L. (IT) | 2026-01-22 | — | — | US | disclosed |
| US-20250375505-A1 | COMPOSITIONS AND METHODS FOR MODIFYING BILE ACIDS TO REGULATE LIPID AND STEROID METABOLISM | UNIV CALIFORNIA (US) | 2025-12-11 | — | — | US | disclosed |
| WO-2025051692-A1 | DETOXIFYING PEPTIDE | REGENTIS PHARMA (FR) | 2025-03-13 | — | — | WO | disclosed |
| CN-119317362-A | Pet food compositions and methods for reducing metabolites associated with protein spoilage in felines | 希尔氏宠物营养品公司 | 2025-01-14 | — | — | CN | disclosed |
| US-20240293472-A1 | Bee Product Extracts, Methods of Production, and Uses Thereof | QUANTUM TECHNOLOGIES LIMITED (NZ) | 2024-09-05 | — | — | US | disclosed |
| US-6890754-B2 | Epidermis/dermis equivalents and aged skin equivalents shaped therefrom | L'OREAL (FR) | 2005-05-10 | — | — | US | disclosed |
| WO-2005033705-A1 | METHODS AND COMPOSITIONS FOR DIAGNOSING MUSCULOSKELETAL, ARTHRITIC AND JOINT DISORDERS BY BIOMARKER DATING | DUKE UNIVERSITY (US) | 2005-04-14 | — | — | WO | disclosed |
| US-20040052772-A1 | Novel epidermis/dermis equivalents and aged skin equivalents shaped therefrom | SOCIETE L'OREAL S.A. | 2004-03-18 | — | — | US | disclosed |
| EP-1317765-A2 | AUTOMATED IDENTIFICATION OF PEPTIDES | Oxford GlycoSciences (UK) Limited (GB) | 2003-06-11 | — | — | EP | disclosed |
| WO-2002021139-A2 | AUTOMATED IDENTIFICATION OF PEPTIDES | OXFORD GLYCOSCIENCES (UK) LTD. (GB) | 2002-03-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250375505-A1 | COMPOSITIONS AND METHODS FOR MODIFYING BILE ACIDS TO REGULATE LIPID AND STEROID METABOLISM | CYP27A1, LIPC, CYP46A1 | GSR 269/4885GRM8 1972/4885GRM6 956/4885 |
| US-20140154257-A1 | Materials and methods for diagnosing and treating asthma and dietary Fru-AGEs related disorders including auto-immune and other diseases found to be associated with elevated RAGE. The specification describes methods to identify and make dietary derived advanced glycation end-products, known as Fru-AGEs, Fru-AGE-haptens, and Fru-AGE immune complexes, and to make monoclonal and polyclonal antibodies to this plurality of bio-molecules for use in immunoassays and for use as therapeutic agents | AGER, FABP2, FCER2 | GSR 1713/4885GRM8 804/4885GRM6 1577/4885 |
| US-20260022384-A1 | ASPARAGINE SYNTHETASE INHIBITORS AND USES THEREOF | ASNS, AARS1, NARS1 | GSR 2917/4885GRM8 4765/4885GRM6 4785/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.